Xtant Medical Valuation Multiples

Xtant Medical Overview

About Xtant Medical

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

Founded

2006

HQ

Employees

232

Website

xtantmedical.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $129M

EBITDA: $13M

EV

$102M

Valuation Multiples

Multiples.vc

Start free trial

Xtant Medical Financials

Xtant Medical reported last 12-month revenue of $129M and EBITDA of $13M.

In the same LTM period, Xtant Medical generated $84M in gross profit, $13M in EBITDA, and $4M in net income.

Xtant Medical P&L

In the most recent fiscal year, Xtant Medical reported revenue of $117M and EBITDA of $800K.

Xtant Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Xtant Medical Stock Performance

Xtant Medical has current market cap of $80M, and enterprise value of $102M.

Xtant Medical's stock price is $0.57.

Xtant Medical Valuation Multiples

Xtant Medical trades at 0.8x EV/Revenue multiple, and 7.7x EV/EBITDA.

Xtant Medical Financial Valuation Multiples

As of March 13, 2026, Xtant Medical has market cap of $80M and EV of $102M.

Equity research analysts estimate Xtant Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Xtant Medical has a P/E ratio of 22.7x.

Xtant Medical Margins & Growth Rates

Xtant Medical's revenue in the last 12 month declined by (10%).

Xtant Medical's revenue per employee in the last FY averaged $0.6M.

Xtant Medical's rule of 40 is 0% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Xtant Medical's rule of X is (16%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Xtant Medical Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Xtant Medical M&A Activity

Xtant Medical acquired XXX companies to date.

Last acquisition by Xtant Medical was on XXXXXXXX, XXXXX. Xtant Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Xtant Medical Investment Activity

Xtant Medical invested in XXX companies to date.

Xtant Medical made its latest investment on XXXXXXXX, XXXXX. Xtant Medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).